Lipocine Inc. is a biopharmaceutical company that develops oral medications using proprietary lipidic delivery technology to improve the absorption and patient compliance of difficult-to-deliver molecules. The company's commercial product is TLANDO, an oral testosterone replacement therapy for male hypogonadism, which it licenses to partners in the United States, Canada, South Korea, and other territories in exchange for upfront payments, milestone payments, and royalties on net sales. Lipocine's pipeline includes next-generation testosterone candidates and a development stage neuroactive steroid program targeting high-unmet-need conditions such as postpartum depression, major depressive disorder, epilepsy, and essential tremor, along with other candidates in liver disease and weight management.